Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

It was developed with Sanofi (NASDAQ: SNY), who actually claims the revenues and splits profits with Regeneron. Regeneron posts their portion of Dupixent as collaboration revenue. Regeneron and ...

Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...

FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi (NASDAQ:SNY – Free Report) – Stock analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Sanofi in a research note issued to investors on Wednesday, March 5th.

Product revenues from Aldurazyme totaled $39 million, down 9% year over year, likely due to the unfavorable timing of order fulfillment to Sanofi SNY. BioMarin signed a collaboration agreement ...